European CHMP recommends approval of risdiplam (Evrysdi) for treatment of spinal muscular atrophy

Risdiplam is an oral SMN2 mRNA splicing modifier, which has demonstrated benefits in altering the clinical course of the disease, allowing patients with Type 1, Type 2 or Type 3 or with one to four SMN2 copies to achieve developmental milestones.

Source:

European Medicines Agency